Tag: porcine epidemic diarrhea vaccines market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Porcine Epidemic Diarrhea Vaccines Market Forecast: What Value Will The Market Reach By 2030?#_x000D_

The porcine epidemic diarrhea vaccines market has experienced substantial growth in recent years. It is projected to increase from $1.8 billion in 2025 to $1.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. The expansion observed in prior periods can be attributed to various factors, including recurring outbreaks of porcine epidemic diarrhea, high mortality rates among neonatal piglets, economic losses incurred by the swine industry, the limited efficacy of non-vaccine disease control measures, and an enhanced reliance on veterinary-led disease prevention strategies._x000D_

_x000D_

The porcine epidemic diarrhea vaccines market is projected to experience robust expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $2.5 billion, growing at a compound annual growth rate (CAGR) of 6.7%. Several factors are expected to fuel this growth during the forecast period, including the proliferation of intensive pig farming practices, an increasing worldwide appetite for pork products, greater understanding of the advantages of herd immunity, the expansion of structured hog production facilities, and supportive government programs for animal health. Key trends shaping the market over the forecast period encompass a wider embrace of preventive vaccination within swine health management, a developing preference for live vaccines in areas where the disease is prevalent, an escalating focus on immunizing piglets early, the expansion of vaccination initiatives in commercial hog operations, and an enhanced focus on biosecurity and disease control measures._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=55004263&type=smp&name=Porcine%20Epidemic%20Diarrhea%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Porcine Epidemic Diarrhea Vaccines Market Growth Backed By Core Demand Fundamentals#_x000D_

The anticipated expansion of pig farming is set to drive the future growth of the porcine epidemic diarrhea vaccine market. This practice encompasses the raising of domestic pigs for various purposes, including meat production, breeding, rearing, comprehensive management of animals from birth until they reach market weight, and the subsequent production and sale of pork products. This increase in pig farming is fueled by factors such as the rising global appetite for pork, progress in breeding and herd management techniques, enhancements in swine production technologies, and the widening reach of commercial pork markets. Within pig farming, porcine epidemic diarrhea (PED) vaccines are vital, contributing to the prevention and control of disease outbreaks, commonly administered during the gestation of sows to confer passive immunity to their newborn piglets. As an illustration, the U.S. Department of Agriculture, a US-based government agency, forecasted in April 2024 that U.S. pork production would hit 12.7 million metric tons, indicating a rise in swine output and reinforcing the ongoing growth of the pig farming industry. Consequently, the expansion of pig farming is a key driver for the growth of the porcine epidemic diarrhea vaccine market._x000D_

_x000D_

#Porcine Epidemic Diarrhea Vaccines Market Segment Analysis Spotlighting Growth Areas#_x000D_

The porcine epidemic diarrhea vaccines market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Live Vaccines, Killed Vaccines_x000D_

2) By Application: Piglets, Adults Pigs_x000D_

3) By End-User: Veterinary Hospitals, Hog Production Farms_x000D_

_x000D_

Subsegments:_x000D_

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines _x000D_

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines_x000D_

_x000D_

#Porcine Epidemic Diarrhea Vaccines Market Growth Trends Reshaping The Competitive Landscape#_x000D_

Leading companies in the Porcine Epidemic Diarrhea (PED) vaccines market are focusing on developing innovative solutions, such as next-generation inactivated and recombinant vaccines, to improve immunity and offer broader protection against emerging PEDV strains. These advanced next-generation inactivated and recombinant vaccines employ either killed viruses or engineered viral proteins to stimulate strong, targeted immunity while enhancing safety and defense against evolving disease strains. For example, in August 2024, Zoetis Inc., a US-based animal health company, secured a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and was also granted a conditional license by the U.S. Department of Agriculture (USDA) for a PEDV vaccine for pigs. These actions solidify Zoetis’s position in developing advanced swine health solutions by supporting further research, boosting vaccine effectiveness, and extending protection against new PEDV strains._x000D_

_x000D_

#Porcine Epidemic Diarrhea Vaccines Market Leading Companies: Who Holds The Strongest Market Presence?#_x000D_

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines _x000D_

_x000D_

#View The Full Porcine Epidemic Diarrhea Vaccines Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Porcine Epidemic Diarrhea Vaccines Market Geographic Analysis: Where Is Demand Accelerating Fastest?#_x000D_

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Porcine Epidemic Diarrhea Vaccines Market Size And Revenue Forecast Through 2030

The market for porcine epidemic diarrhea vaccines has experienced robust expansion in recent years. Valued at $1.8 billion in 2025, it is projected to reach $1.94 billion by 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. This historical growth is driven by persistent outbreaks of porcine epidemic diarrhea, elevated mortality among newborn piglets, substantial financial losses within the swine sector, insufficient efficacy from non-vaccine disease management strategies, and a growing dependence on veterinary-directed prevention efforts.

The porcine epidemic diarrhea vaccines market is projected to experience substantial expansion over the coming years, reaching a valuation of $2.5 billion by 2030 with a compound annual growth rate (CAGR) of 6.7%. This anticipated growth in the forecast period is driven by factors such as the rise of intensive pig farming operations, a growing worldwide appetite for pork, heightened recognition of the benefits associated with herd immunity, the enlargement of organized hog production facilities, and supportive governmental initiatives focusing on animal health. Key trends shaping the forecast period encompass a greater uptake of preventive vaccination within swine health management, a heightened preference for live vaccines in regions where the disease is endemic, an increased emphasis on early immunization of piglets, the broadening of vaccination programs within commercial hog farms, and a stronger focus on implementing biosecurity measures and disease control protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Porcine Epidemic Diarrhea Vaccines Market Demand Drivers: What Is Fueling Industry Growth?

Expanding pig farming operations are anticipated to drive growth in the porcine epidemic diarrhea vaccine market moving forward. This type of farming revolves around raising domestic pigs for meat, encompassing breeding, rearing, and managing animals from birth until they reach market weight, as well as producing and selling pork products. This expansion is fueled by rising global pork demand, improvements in breeding techniques and herd management, technological advancements in swine production systems, and the growth of commercial pork markets. Vaccines for porcine epidemic diarrhea (PED) are essential in this context, as they help prevent and control disease outbreaks; they are typically administered during the sow’s gestation period to transfer passive immunity to newborn piglets. As an example, in April 2024, the U.S. Department of Agriculture, a government agency based in the United States, forecasted that U.S. pork production would reach 12.7 million metric tons, indicating increased swine output and supporting ongoing growth in the pig farming industry. Consequently, the rise in pig farming is fueling the expansion of the porcine epidemic diarrhea vaccine market.

Porcine Epidemic Diarrhea Vaccines Market Segmentation Trends And Revenue Drivers

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

Porcine Epidemic Diarrhea Vaccines Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating innovative products like next-generation inactivated and recombinant vaccines to boost immune responses and offer wider protection against new PEDV strains. These advanced vaccines utilize either killed viruses or engineered viral proteins to elicit strong, targeted immunity while improving safety and defending against evolving disease variants. For example, in August 2024, Zoetis Inc., a United States-based animal health company, was awarded a grant for research on the Porcine Epidemic Diarrhea Virus (PEDV) vaccine and also secured a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine designed to combat PEDV in pigs. These initiatives reinforce Zoetis’s position in advancing swine health solutions by enabling further studies, boosting vaccine efficacy, and broadening defense against emerging PEDV strains.

Porcine Epidemic Diarrhea Vaccines Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Access The Complete Porcine Epidemic Diarrhea Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Porcine Epidemic Diarrhea Vaccines Market Leading Geography: Which Region Generates The Most Revenue?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Porcine Epidemic Diarrhea Vaccines Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The porcine epidemic diarrhea vaccines market has experienced substantial growth in recent years. It is projected to expand from $1.8 billion in 2025 to $1.94 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. This historical growth can be linked to recurring outbreaks of porcine epidemic diarrhea, significant mortality rates among newborn piglets, financial setbacks for the swine industry, the constrained efficacy of non-vaccine disease management methods, and a heightened dependence on veterinary-guided disease prevention.

The porcine epidemic diarrhea vaccines market is projected to experience substantial growth in the coming years. It is anticipated to reach $2.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period can be attributed to the rise of intensive pig farming practices, increasing global demand for pork products, a heightened awareness of herd immunity benefits, the expansion of organized hog production farms, and supportive government animal health initiatives. Major trends in the forecast period include the increasing adoption of preventive vaccination in swine health management, a growing preference for live vaccines in endemic regions, a rising focus on early immunization of piglets, the expansion of vaccination programs in commercial hog farms, and a greater emphasis on biosecurity and disease control protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Core Factors Are Supporting The Expansion Of The Porcine Epidemic Diarrhea Vaccines Market?

Future expansion of the porcine epidemic diarrhea vaccine market is anticipated due to the rising trend in pig farming. This practice encompasses the cultivation of domestic pigs for various purposes, including meat production, breeding activities, animal rearing, overseeing livestock from birth until they reach market weight, and the subsequent production and commercialization of pork items. Several factors contribute to the growth of pig farming, such as increasing worldwide demand for pork, progress in breeding techniques and herd management, technological enhancements in swine production, and the expansion of commercial pork sales channels. Porcine epidemic diarrhea (PED) vaccines are vital in pig farming, as they aid in preventing and controlling disease outbreaks; these vaccines are typically given during the gestation period of sows to confer passive immunity to their offspring. For example, the U.S. Department of Agriculture, a US-based government agency, reported in April 2024 a projection of U.S. pork production reaching 12.7 million metric tons, indicating a rise in swine output that fosters ongoing growth in the pig farming industry. Consequently, the expansion of pig farming is a key factor propelling the development of the porcine epidemic diarrhea vaccine market.

Which Segment Divisions Form The Structure Of The Porcine Epidemic Diarrhea Vaccines Market?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

What Trends Are Affecting The Porcine Epidemic Diarrhea Vaccines Market Dynamics?

Leading companies operating in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on developing innovative solutions, such as next-generation inactivated and recombinant vaccines, to enhance immunity and provide broader protection against emerging PEDV strains. These advanced vaccines, whether inactivated or recombinant, employ either killed viruses or engineered viral proteins to trigger strong, targeted immunity, while also improving safety and defense against evolving disease strains. For instance, in August 2024, Zoetis Inc., a US-based animal health company, was awarded a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and also received a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine designed to combat PEDV in pigs. These actions reinforce Zoetis’s contribution to developing advanced swine health solutions by supporting further research, boosting vaccine effectiveness, and expanding protection against emerging PEDV strains.

Who Are The Companies Shaping The Porcine Epidemic Diarrhea Vaccines Market Landscape?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Access The Complete Porcine Epidemic Diarrhea Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Accounts For The Highest Share Of The Porcine Epidemic Diarrhea Vaccines Market?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Porcine Epidemic Diarrhea Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Porcine Epidemic Diarrhea Vaccines Market From 2026 To 2030?

The porcine epidemic diarrhea vaccines market size has shown considerable growth in recent years. It is projected to expand from $1.8 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The observed growth in the historic period can be attributed to persistent outbreaks of porcine epidemic diarrhea, elevated mortality rates among neonatal piglets, financial setbacks in the swine industry, the constrained effectiveness of non-vaccine disease control measures, and an increased reliance on veterinary-led disease prevention.

The porcine epidemic diarrhea vaccines market is expected to demonstrate significant expansion in the coming years. It is projected to achieve a value of $2.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This anticipated growth can be attributed to several factors, including the increase in intensive pig farming practices, the rising worldwide demand for pork products, a greater understanding of the advantages of herd immunity, the spread of organized hog production farms, and supportive government initiatives concerning animal health. Prominent trends expected in the forecast period involve a heightened adoption of preventive vaccination within swine health management, a growing preference for live vaccines in regions where the disease is common, an increased emphasis on the early immunization of piglets, the extension of vaccination programs in commercial hog farms, and a stronger focus on biosecurity and disease control protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Major Drivers Are Influencing The Expansion Of The Porcine Epidemic Diarrhea Vaccines Market?

The escalating practice of pig farming is anticipated to drive the expansion of the porcine epidemic diarrhea vaccine market in the forthcoming period. This agricultural activity encompasses the raising of domestic pigs for meat, their breeding, rearing, and management from birth to market weight, alongside the production and marketing of pork products. The surge in pig farming is fueled by increasing global demand for pork, progress in breeding and herd management techniques, enhancements in swine production technologies, and the expansion of commercial pork sectors. Porcine epidemic diarrhea (PED) vaccines are essential in pig farming, assisting in the prevention and control of disease outbreaks, commonly administered during a sow’s gestation to impart passive immunity to newborn piglets. For example, in April 2024, the U.S. Department of Agriculture, a US-based government agency, forecast U.S. pork production to hit 12.7 million metric tons, indicating a rise in swine output and thereby backing the ongoing growth of the pig farming industry. Consequently, the expansion of pig farming is stimulating the growth of the porcine epidemic diarrhea vaccine market.

How Is The Porcine Epidemic Diarrhea Vaccines Market Segmented Across Different Segment Categories?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

What Trends Are Transforming The Porcine Epidemic Diarrhea Vaccines Market?

Leading companies within the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on the development of innovative solutions, including next-generation inactivated and recombinant vaccines, to improve immunity and deliver broader safeguarding against emergent PEDV strains. Next-generation inactivated and recombinant vaccines represent advanced immunization methods that utilize either deactivated viruses or engineered viral proteins to stimulate strong, targeted immune responses, simultaneously enhancing safety and defense against evolving disease strains. As an illustration, in August 2024, Zoetis Inc., a US-based animal health company, received funding for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and was also granted a conditional license by the U.S. Department of Agriculture (USDA) for a vaccine intended to combat PEDV in pigs. These endeavors reinforce Zoetis’s critical contribution to developing sophisticated swine health solutions by supporting further scientific inquiry, improving vaccine effectiveness, and extending protection against new PEDV strains.

Which Organizations Play A Role In The Porcine Epidemic Diarrhea Vaccines Market Landscape?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Get The Full Porcine Epidemic Diarrhea Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Leads The Porcine Epidemic Diarrhea Vaccines Market In Overall Market Size?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Porcine Epidemic Diarrhea Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Porcine Epidemic Diarrhea Vaccines Market Expected To Change Between 2026 And 2030?

The market for porcine epidemic diarrhea vaccines has demonstrated robust expansion recently. Projections indicate a rise in its valuation from $1.8 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this growth has been driven by factors such as recurrent outbreaks of porcine epidemic diarrhea, elevated mortality rates among neonatal piglets, financial setbacks experienced by the swine industry, the restricted efficacy of non-vaccine disease management strategies, and an increased dependence on veterinary-guided disease prevention.

The porcine epidemic diarrhea vaccines market is set to experience robust expansion over the next few years, with its size projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This forecasted growth is primarily influenced by the rise of intensive pig farming practices, increasing global consumption of pork products, growing awareness of the benefits of herd immunity, the expansion of structured hog production farms, and supportive government initiatives for animal health. Significant trends expected during this period include a greater adoption of preventive vaccination in swine health management, a rising preference for live vaccines in regions where the disease is endemic, an increased focus on the early immunization of piglets, the broadening of vaccination programs in commercial hog farms, and an enhanced emphasis on biosecurity and disease control protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Major Factors Are Driving The Expansion Of The Porcine Epidemic Diarrhea Vaccines Market?

Growing pig farming is anticipated to drive the expansion of the porcine epidemic diarrhea vaccine market in the future. This sector encompasses the raising of domestic pigs for meat, including breeding, rearing, managing animals from birth to market weight, and the production and commercialization of pork items. The surge in pig farming is fueled by increasing global pork demand, enhancements in breeding and herd management techniques, technological strides in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are vital for pig farming, assisting in the prevention and control of disease outbreaks, often administered during the sow’s gestation to confer passive immunity to newborn piglets. As an illustration, in April 2024, the U.S. Department of Agriculture, a US-based government agency, forecast U.S. pork production to hit 12.7 million metric tons. This projection signifies heightened swine output and underpins the ongoing growth of the pig farming industry. Consequently, the expansion of pig farming is stimulating the growth of the porcine epidemic diarrhea vaccine market.

How Is The Porcine Epidemic Diarrhea Vaccines Market Structured Across Different Segments?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

Which Trends Are Shaping The Future Of The Porcine Epidemic Diarrhea Vaccines Market?

Leading firms within the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating cutting-edge solutions, including next-generation inactivated and recombinant vaccines, to improve immunity and offer wider safeguarding against new PEDV strains. These next-generation inactivated and recombinant vaccines function by employing either deactivated viruses or genetically modified viral proteins to induce robust, specific immune responses, thereby increasing safety and defense against evolving disease strains. A notable example is Zoetis Inc., a US-based animal health company, which in August 2024, secured a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and also obtained a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine targeting PEDV in pigs. Such initiatives reinforce Zoetis’s position in crafting advanced swine health solutions by fostering additional research, boosting vaccine effectiveness, and broadening the scope of protection against emerging PEDV strains.

Which Major Players Dominate The Porcine Epidemic Diarrhea Vaccines Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Read the full porcine epidemic diarrhea vaccines market report here:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Currently Holds The Largest Share Of The Porcine Epidemic Diarrhea Vaccines Market?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Porcine Epidemic Diarrhea Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Porcine Epidemic Diarrhea Vaccines Market Expected To Change Between 2026 And 2030?

The market for porcine epidemic diarrhea vaccines has demonstrated robust expansion recently. Projections indicate a rise in its valuation from $1.8 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this growth has been driven by factors such as recurrent outbreaks of porcine epidemic diarrhea, elevated mortality rates among neonatal piglets, financial setbacks experienced by the swine industry, the restricted efficacy of non-vaccine disease management strategies, and an increased dependence on veterinary-guided disease prevention.

The porcine epidemic diarrhea vaccines market is set to experience robust expansion over the next few years, with its size projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This forecasted growth is primarily influenced by the rise of intensive pig farming practices, increasing global consumption of pork products, growing awareness of the benefits of herd immunity, the expansion of structured hog production farms, and supportive government initiatives for animal health. Significant trends expected during this period include a greater adoption of preventive vaccination in swine health management, a rising preference for live vaccines in regions where the disease is endemic, an increased focus on the early immunization of piglets, the broadening of vaccination programs in commercial hog farms, and an enhanced emphasis on biosecurity and disease control protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Major Factors Are Driving The Expansion Of The Porcine Epidemic Diarrhea Vaccines Market?

Growing pig farming is anticipated to drive the expansion of the porcine epidemic diarrhea vaccine market in the future. This sector encompasses the raising of domestic pigs for meat, including breeding, rearing, managing animals from birth to market weight, and the production and commercialization of pork items. The surge in pig farming is fueled by increasing global pork demand, enhancements in breeding and herd management techniques, technological strides in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are vital for pig farming, assisting in the prevention and control of disease outbreaks, often administered during the sow’s gestation to confer passive immunity to newborn piglets. As an illustration, in April 2024, the U.S. Department of Agriculture, a US-based government agency, forecast U.S. pork production to hit 12.7 million metric tons. This projection signifies heightened swine output and underpins the ongoing growth of the pig farming industry. Consequently, the expansion of pig farming is stimulating the growth of the porcine epidemic diarrhea vaccine market.

How Is The Porcine Epidemic Diarrhea Vaccines Market Structured Across Different Segments?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

Which Trends Are Shaping The Future Of The Porcine Epidemic Diarrhea Vaccines Market?

Leading firms within the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating cutting-edge solutions, including next-generation inactivated and recombinant vaccines, to improve immunity and offer wider safeguarding against new PEDV strains. These next-generation inactivated and recombinant vaccines function by employing either deactivated viruses or genetically modified viral proteins to induce robust, specific immune responses, thereby increasing safety and defense against evolving disease strains. A notable example is Zoetis Inc., a US-based animal health company, which in August 2024, secured a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and also obtained a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine targeting PEDV in pigs. Such initiatives reinforce Zoetis’s position in crafting advanced swine health solutions by fostering additional research, boosting vaccine effectiveness, and broadening the scope of protection against emerging PEDV strains.

Which Major Players Dominate The Porcine Epidemic Diarrhea Vaccines Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Read the full porcine epidemic diarrhea vaccines market report here:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Currently Holds The Largest Share Of The Porcine Epidemic Diarrhea Vaccines Market?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Porcine Epidemic Diarrhea Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Porcine Epidemic Diarrhea Vaccines Market Expected To Change Between 2026 And 2030?

The market for porcine epidemic diarrhea vaccines has demonstrated robust expansion recently. Projections indicate a rise in its valuation from $1.8 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this growth has been driven by factors such as recurrent outbreaks of porcine epidemic diarrhea, elevated mortality rates among neonatal piglets, financial setbacks experienced by the swine industry, the restricted efficacy of non-vaccine disease management strategies, and an increased dependence on veterinary-guided disease prevention.

The porcine epidemic diarrhea vaccines market is set to experience robust expansion over the next few years, with its size projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This forecasted growth is primarily influenced by the rise of intensive pig farming practices, increasing global consumption of pork products, growing awareness of the benefits of herd immunity, the expansion of structured hog production farms, and supportive government initiatives for animal health. Significant trends expected during this period include a greater adoption of preventive vaccination in swine health management, a rising preference for live vaccines in regions where the disease is endemic, an increased focus on the early immunization of piglets, the broadening of vaccination programs in commercial hog farms, and an enhanced emphasis on biosecurity and disease control protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Major Factors Are Driving The Expansion Of The Porcine Epidemic Diarrhea Vaccines Market?

Growing pig farming is anticipated to drive the expansion of the porcine epidemic diarrhea vaccine market in the future. This sector encompasses the raising of domestic pigs for meat, including breeding, rearing, managing animals from birth to market weight, and the production and commercialization of pork items. The surge in pig farming is fueled by increasing global pork demand, enhancements in breeding and herd management techniques, technological strides in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are vital for pig farming, assisting in the prevention and control of disease outbreaks, often administered during the sow’s gestation to confer passive immunity to newborn piglets. As an illustration, in April 2024, the U.S. Department of Agriculture, a US-based government agency, forecast U.S. pork production to hit 12.7 million metric tons. This projection signifies heightened swine output and underpins the ongoing growth of the pig farming industry. Consequently, the expansion of pig farming is stimulating the growth of the porcine epidemic diarrhea vaccine market.

How Is The Porcine Epidemic Diarrhea Vaccines Market Structured Across Different Segments?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

Which Trends Are Shaping The Future Of The Porcine Epidemic Diarrhea Vaccines Market?

Leading firms within the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating cutting-edge solutions, including next-generation inactivated and recombinant vaccines, to improve immunity and offer wider safeguarding against new PEDV strains. These next-generation inactivated and recombinant vaccines function by employing either deactivated viruses or genetically modified viral proteins to induce robust, specific immune responses, thereby increasing safety and defense against evolving disease strains. A notable example is Zoetis Inc., a US-based animal health company, which in August 2024, secured a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and also obtained a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine targeting PEDV in pigs. Such initiatives reinforce Zoetis’s position in crafting advanced swine health solutions by fostering additional research, boosting vaccine effectiveness, and broadening the scope of protection against emerging PEDV strains.

Which Major Players Dominate The Porcine Epidemic Diarrhea Vaccines Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Read the full porcine epidemic diarrhea vaccines market report here:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Currently Holds The Largest Share Of The Porcine Epidemic Diarrhea Vaccines Market?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Porcine Epidemic Diarrhea Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the porcine epidemic diarrhea vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Porcine Epidemic Diarrhea Vaccines Market’s size between 2026 and 2030?

The porcine epidemic diarrhea vaccines market size has experienced strong growth in recent years. It is forecast to rise from $1.8 billion in 2025 to $1.94 billion in 2026, with a compound annual growth rate (CAGR) of 7.6%. This historical expansion can be attributed to factors including recurrent porcine epidemic diarrhea outbreaks, high mortality rates observed in neonatal piglets, economic losses incurred by the swine industry, the limited effectiveness of non-vaccine disease control measures, and an increasing reliance on veterinary-guided disease prevention.

The porcine epidemic diarrhea vaccines market size is anticipated to undergo significant expansion in the foreseeable future. This market is projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate of 6.7%. The expansion over the forecast period is fueled by the rise of intensive pig farming methods, an increasing global appetite for pork, greater recognition of the advantages of herd immunity, the proliferation of organized hog production farms, and supportive government initiatives concerning animal health. Prominent trends expected during this period include a wider adoption of preventive vaccination in swine health management, a growing inclination towards live vaccines in endemic regions, an intensified focus on early immunization for piglets, the broadening of vaccination programs within commercial hog farms, and a stronger emphasis on biosecurity and protocols for disease control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Drivers Are Shaping Strategic Decisions In The Porcine Epidemic Diarrhea Vaccines Market?

Growing pig farming is anticipated to drive the expansion of the porcine epidemic diarrhea vaccine market in the future. This practice encompasses the raising of domestic swine for meat, along with activities like breeding, rearing, managing pigs from birth to market readiness, and the production and sale of pork products. The increase in pig farming stems from escalating worldwide demand for pork, progress in breeding and herd management techniques, enhancements in swine production technologies, and the expansion of commercial pork sectors. Porcine epidemic diarrhea (PED) vaccines are vital in pig farming, assisting in the prevention and control of disease outbreaks, usually given during a sow’s gestation to confer passive immunity to her offspring. An example of this growth is seen in April 2024, when the U.S. Department of Agriculture, a US government body, forecast U.S. pork production to hit 12.7 million metric tons, indicating higher swine output and bolstering the ongoing development of the pig farming industry. Consequently, the expansion of pig farming is stimulating the growth of the porcine epidemic diarrhea vaccine market.

What Segment Categories Are Covered In The Porcine Epidemic Diarrhea Vaccines Market?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

How Are Emerging Trends Affecting The Progression Of The Porcine Epidemic Diarrhea Vaccines Market?

Leading companies within the Porcine Epidemic Diarrhea (PED) vaccines market are prioritizing the creation of innovative solutions, including next-generation inactivated and recombinant vaccines, to boost immunity and offer wider safeguard against novel PEDV strains. These advanced vaccines utilize either killed viruses or engineered viral proteins to provoke robust, specific immune responses, concurrently enhancing safety and defense against mutating pathogens. For instance, in August 2024, Zoetis Inc., a US-based animal health company, was awarded funding related to Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and also obtained a provisional authorization from the U.S. Department of Agriculture (USDA) for a vaccine designed to combat PEDV in pigs. Such endeavors reinforce Zoetis’s position in crafting advanced swine health solutions by promoting additional investigation, improving vaccine efficacy, and broadening safeguarding against emerging PEDV strains.

Which Key Players Are Driving Competition In The Porcine Epidemic Diarrhea Vaccines Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Is Projected To Lead The Porcine Epidemic Diarrhea Vaccines Market During The Forecast Period?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Porcine Epidemic Diarrhea Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

Browse Through More Reports Similar to the Global Porcine Epidemic Diarrhea Vaccines Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Porcine Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Swine Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the bevacizumab biosimilars market from 2025–2034 with trusted insights from The Business Research Company

How Will The Bevacizumab Biosimilars Market Size Evolve Between Now And 2029?

The porcine epidemic diarrhea vaccines market has demonstrated robust growth in recent years. This market is anticipated to expand from $1.67 billion in 2024 to $1.8 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.7%. The historical increase can be attributed to elements such as large-scale vaccination campaigns, expanded programs on immunization (EPI), the adoption of disposable syringes, diarrhea eradication efforts, and initiatives like the global alliance for vaccines and immunization (GAVI).

The porcine epidemic diarrhea vaccines market size is projected to experience significant expansion in the coming years, with an anticipated growth to $2.37 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.1%. This projected growth throughout the forecast period stems from an increased focus on immunization programs, an expanding pipeline for vaccine development, growing pig populations, a concentrated effort on cold chain management, and heightened awareness regarding the importance of preventive healthcare strategies. Noteworthy trends expected during this period include continuous innovations in vaccine delivery device technology, a move towards needle-free solutions, advancements within personalized medicine, an increasing preference for self-administered vaccines, and the bolstering of animal healthcare infrastructure and distribution networks.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Key Drivers Are Powering Growth In The Bevacizumab Biosimilars Market?

The anticipated expansion of pig farming is set to boost the porcine epidemic diarrhea vaccine market in the future. Pig farming encompasses the raising of domestic swine for meat, including breeding, rearing, management from birth to market weight, and the marketing and sale of pork products. This growth in pig farming stems from escalating worldwide demand for pork, enhanced breeding and management techniques, innovations in agricultural technology, and a broadening consumer base for pork. To prevent and control outbreaks, porcine epidemic diarrhea (PED) vaccines are utilized in pig farming operations. These vaccines are commonly given either by injection or orally, beginning during the sow’s gestation, to provide passive immunity to newborn piglets through their colostrum. As an illustration, the United States Department of Agriculture, a US government body, reported that in 2022, pork production in the United States amounted to 40.6 billion pounds, showing a 1 percent rise from the prior year. Consequently, the expansion of pig farming is fueling the growth of the porcine epidemic diarrhea vaccine market.

How Is The Global Bevacizumab Biosimilars Market Structured By Key Segments?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

What Future-Focused Trends Are Anticipated In The Bevacizumab Biosimilars Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are focused on developing innovative products, such as the porcine parvovirus (PPV) vaccine, to strengthen their market standing. The Porcine Parvovirus (PPV) vaccine is a veterinary immunization specifically formulated to prevent reproductive failure in pigs, which is caused by PPV, a small, non-enveloped virus linked to conditions like infertility, stillbirths, mummified fetuses, and the birth of weak piglets. For instance, in March 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, introduced the ReproCyc ParvoFLEX porcine parvovirus (PPV) vaccine. This cutting-edge vaccine is engineered to counteract reproductive issues in pigs, including infertility, stillbirths, mummified fetuses, and weak piglets, all stemming from the PPV, a small, non-enveloped virus. The distinctiveness of this introduction comes from the advanced formulation and proven efficacy of the vaccine, which delivers extensive protection against PPV-induced reproductive losses, thereby securing the health and productivity of pig herds.

Which Companies Hold A Competitive Edge In The Bevacizumab Biosimilars Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, Elanco Animal Health, Idexx Laboratories Inc., Bio-Rad Laboratories Inc., Ceva Santé Animale Health Company, Phibro Animal Health Corporation, Benchmark Animal Health Ltd., IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Tecnovax, Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Komipharm International Co. Ltd., Boehringer Ingelheim Animal Health, MSD Animal Health, Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Region Is Expected To Lead The Bevacizumab Biosimilars Market In The Next Few Years?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2024. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2025, By The Business Research Company

Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Pediatric Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Projected Valuation Of The Porcine Epidemic Diarrhea Vaccines Market In The Coming Years?

In recent times, there has been a significant expansion in the market size of porcine epidemic diarrhea vaccines. The market is projected to increase from $1.67 billion in 2024 to $1.8 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%. The considerable growth noted during the historic period can be credited to extensive vaccination campaigns, the enlargement of immunization programs, the utilization of one-time usage syringes, endeavor to eliminate diarrhea, and initiatives like the global alliance for vaccines and immunization (GAVI).

The market for porcine epidemic diarrhea vaccines is projected to witness notable expansion in the forthcoming years, escalating to $2.37 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%. The anticipated growth throughout this period can be linked to the increasing focus on immunization initiatives, advancements in vaccine creation pathways, burgeoning pig populations, emphasis on cold chain management systems, and heightened awareness regarding the necessity of preventive health measures. The forecast period also suggests ongoing innovation in vaccine delivery equipment technology, emphasizing needle-free solutions, progression in customized medicine, a rising inclination towards self-administered vaccines, and fortification of animal healthcare infrastructure and distribution channels.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Porcine Epidemic Diarrhea Vaccines Market?

The surge in pig farming is set to fuel the expansion of the porcine epidemic diarrhea vaccine market in the future. This type of farming entails raising domestic pigs for purposes such as meat production, breeding, rearing from birth to saleable weight, and the marketing and selling of pork products. The growth in pig farming can be attributed to the increasing global demand for pork, enhanced breeding and management methods, advancements in farming technology, and the growth of markets for pork consumption. Porcine epidemic diarrhea (PED) vaccines play a crucial role in pig farming in order to control and prevent disease outbreaks, usually administered as an injection or orally from the sow’s gestation period to pass on passive immunity to newborn piglets via colostrum. For instance, data from the United States Department of Agriculture, a US-based government body, shows that in 2022, pork production in the United States came in at 40.6 billion pounds, showing a rise of 1 percent compared to the preceding year. Consequently, the surge in pig farming is playing a key role in driving the expansion of the porcine epidemic diarrhea vaccine market.

Which Segmentation Categories Are Highlighted In The Porcine Epidemic Diarrhea Vaccines Market Analysis?

The porcine epidemic diarrhea vaccines market covered in this report is segmented –

1) By Product: Live Vaccines, Killed Vaccines

2) By Application: Piglets, Adults Pigs

3) By End-User: Veterinary Hospitals, Hog Production Farms

Subsegments:

1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines

2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines

Which Market Trends Are Expected To Define The Future Of The Porcine Epidemic Diarrhea Vaccines Market?

Leading enterprises in the porcine epidemic diarrhea vaccines market are creating groundbreaking products like the porcine parvovirus (PPV) vaccine to solidify their market presence. The PPV vaccine is an animal-health solution aimed at curtailing reproductive issues in pigs provoked by PPV, a minor, non-encapsulated virus known for causing infertility, stillbirths, mummification of fetuses, and feeble piglets. For instance, Boehringer Ingelheim, a pharmaceutical company based in Germany, recently launched the ReproCyc ParvoFLEX PPV vaccine in March 2022. This state-of-the-art vaccine is engineered to fight reproductive problems in pigs, including infertility, stillbirths, mummified fetuses, and feeble piglets caused by PPV, a minor, non-encapsulated virus. The uniqueness of this product lies in its superior formulation and effectiveness in offering extensive protection against reproductive losses caused by PPV, thereby ensuring the health and productivity of pig populations.

Which Companies Hold A Competitive Edge In The 455 Market?

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, Elanco Animal Health, Idexx Laboratories Inc., Bio-Rad Laboratories Inc., Ceva Santé Animale Health Company, Phibro Animal Health Corporation, Benchmark Animal Health Ltd., IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Tecnovax, Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Komipharm International Co. Ltd., Boehringer Ingelheim Animal Health, MSD Animal Health, Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Porcine Epidemic Diarrhea Vaccines Market?

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2024. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model